Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome
about
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimenThe CD44+/CD24- phenotype is enriched in basal-like breast tumorsGene expression patterns in ovarian carcinomasProteotypic classification of spontaneous and transgenic mammary neoplasmsRecent translational research: microarray expression profiling of breast cancer--beyond classification and prognostic markers?Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancerHER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cellsBiomarkers in triple negative breast cancer: A reviewNetworking galore: intermediate filaments and cell migrationRepeated observation of breast tumor subtypes in independent gene expression data setsThe "portrait" of hereditary breast cancerONCOMINE: a cancer microarray database and integrated data-mining platformDNA copy number alterations and expression of relevant genes in triple-negative breast cancerProteome-wide profiling of the MCF10AT breast cancer progression modelA phenotypic mouse model of basaloid breast tumorsmRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancerA time- and matrix-dependent TGFBR3-JUND-KRT5 regulatory circuit in single breast epithelial cells and basal-like premalignanciesThe Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.Proteomics of breast cancer: principles and potential clinical applications.Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis.Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.Contaminating cells alter gene signatures in whole organ versus laser capture microdissected tumors: a comparison of experimental breast cancers and their lymph node metastases.Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.Identification of breast cancer patients with a high risk of developing brain metastases: a single-institutional retrospective analysis.Keratin 17 in premalignant and malignant squamous lesions of the cervix: proteomic discovery and immunohistochemical validation as a diagnostic and prognostic biomarkerProgesterone receptor isoform functions in normal breast development and breast cancerAnalysis of differentially expressed proteins in oral squamous cell carcinoma by MALDI-TOF MS.Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway.Clinical proteomics of breast cancerCorrelations of ALDH1 expression with molecular subtypes and ABCG2 in breast cancerp16INK4a expression in basal-like breast carcinoma.Identification of prognostic genes for recurrent risk prediction in triple negative breast cancer patients in Taiwan.Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature.Keratin 17 promotes epithelial proliferation and tumor growth by polarizing the immune response in skin.Is the small heat shock protein alphaB-crystallin an oncogene?Understanding tissue context influences on intratumour heterogeneityModeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease.GeneFriends: an online co-expression analysis tool to identify novel gene targets for aging and complex diseases.Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.Estrogen induced breast cancer is the result in the disruption of the asymmetric cell division of the stem cell.
P2860
Q21092375-E2A7D2E3-EC03-4445-8DEB-0D96A0180372Q21092906-EBF07A77-A48A-433F-B359-EBF3DB3DB116Q24644996-B44D14BC-0DA0-40A1-8E4F-DF392A79C38AQ24795869-D0EE4F97-B475-4FC2-9577-AB39CAF871ABQ24806447-7AAF0DE6-D060-4A76-A00F-6EC79227650BQ24810751-A8E68B5B-3E6F-49A9-8356-6BAA44732051Q25257668-91658F2D-48E2-495A-986C-B47ACC1B71BBQ26775094-EB65E8FA-8D14-4BC3-A068-08D111F3FF9CQ27693294-E881E117-D169-4D96-9F06-A06778BC9509Q28131820-D338FCEC-E283-4AB7-A104-0FDA6DA7B7A2Q28238725-6769BB36-DF8C-43B4-9F40-5B45C8DD4F14Q28255103-DB1C2010-D903-4C9F-800E-05F9F4F8B71AQ28271168-D3D5E7FC-5819-437C-839D-EB6DEAC4C0D0Q28474333-1D9FD468-FDAA-4705-86E4-F895D574E312Q28480588-4CBB3BC5-AA44-4ED6-AF5C-96D731862E79Q28543647-357127A9-886A-4552-B468-08F48ADD6307Q30410515-242C9DFA-A021-441D-A075-50E8B7237A34Q30978083-F20F5069-2F13-41A9-99E1-612BC52F41F3Q33245053-B638DEFC-0A21-4ECD-A5BB-E4AC4E72953CQ33280165-135649F6-023B-4C61-8B4B-6E4F580516ABQ33291587-C5D46814-5647-4A5C-B587-8F2B59049577Q33302433-61AE0DD9-73C4-46C2-849C-10E7C1CCA395Q33552870-1845FAA3-F488-4110-B469-CE51D7F5146FQ33553971-A714FB20-9B12-4C4D-88B5-6219EB43FF51Q33634684-D3A7FBE2-DC8F-48BC-9EBA-7316FBC27149Q33693898-D6DD83BD-D283-40CC-9222-686AF94BC4C7Q33774554-682F2E01-4471-47FA-83CB-707AB221BD1BQ33820727-E674C1E6-EE7B-414E-8520-BC228714E64EQ33885885-3F8BD0BF-9410-4D09-8CB5-B2F18D4E9C37Q33972932-BCA2FFC8-4CE9-467F-B99F-6D745B9F0409Q34007463-26B3602B-C8EF-47D7-8859-3463C5762D23Q34091380-94032B93-0879-4298-AB75-D1A29F6D82E3Q34124530-BF9D13BB-59C8-4493-9491-21C442727C98Q34164046-1E0782E5-7867-4DBA-AE69-D2BBB150B642Q34245398-BFC58F06-84D7-445C-887A-C817B7C7F1C4Q34267072-079701D9-524C-4D8E-858C-7BFE29E8E157Q34296534-9A7B601F-0136-4736-8D0F-D41DFB4082C2Q34435173-3276BEA1-A644-498E-BFB1-38564E43BC0CQ34489002-2F9BBC0E-5F22-4799-ACDE-B75531CA0C98Q34508226-042D73F0-9A7D-48E3-9E45-AC64C88B3203
P2860
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Expression of cytokeratins 17 ...... mas with poor clinical outcome
@ast
Expression of cytokeratins 17 ...... mas with poor clinical outcome
@en
Expression of cytokeratins 17 ...... mas with poor clinical outcome
@nl
type
label
Expression of cytokeratins 17 ...... mas with poor clinical outcome
@ast
Expression of cytokeratins 17 ...... mas with poor clinical outcome
@en
Expression of cytokeratins 17 ...... mas with poor clinical outcome
@nl
prefLabel
Expression of cytokeratins 17 ...... mas with poor clinical outcome
@ast
Expression of cytokeratins 17 ...... mas with poor clinical outcome
@en
Expression of cytokeratins 17 ...... mas with poor clinical outcome
@nl
P2093
P2860
P50
P3181
P1476
Expression of cytokeratins 17 ...... mas with poor clinical outcome
@en
P2093
Frank Mross
Guido Sauter
Holger Dieterich
Joachim Torhorst
Juha Kononen
Markus Zuber
Ossi R Köchli
Phillippe Haas
P2860
P304
P3181
P356
10.1016/S0002-9440(10)64476-8
P407
P577
2002-12-01T00:00:00Z